• Applications & Products
    • Applications
    • Products
  • Media Formulation
  • About InVitria
  • News & Blog
  • Contact Us
  • Terms
  • Privacy
  • Sitemap
Performance. Defined.
  • 1-800-916-8311 or Email Us
  • iconMy Account
  • iconView Cart
  • Applications & Products
    • Applications
      • Gene Therapy
      • Cell Therapy
      • T-Cell Immunotherapy
      • Vaccine Production
      • Antibody Production
      • Final Formulation
      • Food Science
    • Product Types
      • Blood-Free Cell Culture Media
      • Cell Culture Components
      • Insulin-Transferrin Supplements
      • Recombinant Albumin
      • Recombinant Transferrin
      • Recombinant Human Lysozyme
      • Recombinant Human Interleukins
    • Products
      • Cellastim S® – Recombinant human albumin
      • Exbumin® – Recombinant human albumin excipient
      • Optibumin® 20 – Recombinant human albumin
      • Optibumin® 25 – Recombinant human albumin
      • Optiferrin® – Recombinant human transferrin
      • Lacromin® – Recombinant human holo lactoferrin
      • ITS AF – Blood-free cell culture media supplement
      • ITSE + A – Blood-free cell culture media supplement
      • ITSE Animal-Free® – Blood-free cell culture media supplement
      • Lysobac® – Recombinant human lysozyme
      • OptiLeukin 2 – Recombinant human IL-2
      • LIF – Leukemia Inhibitory Factor
      • OptiVERO® – Chemically-defined complete VERO media
  • About InVitria
  • News & Blog
  • Contact Us
  • Knowledge Base
  • Applications
  • Products
  • Contact Us
  • Home
  • Applications
  • Gene Therapy

Animal Origin Free Strategies for Gene Therapy Manufacturing and Formulation

High-Performance, Regulatory-Friendly Viral Vector Production for Gene Therapy

After decades of effort, the field of gene therapy has finally reached critical mass. The FDA has now approved two adeno-associated viral vector (AAV) therapies, LUXTURNA (voretigene neparvovec-rzyl) for inherited retinal dystrophy and ZOLGENSMA (onasemnogene abeparvovec-xioi) for pediatric, inherited spinal muscular atrophy. An attenuated, genetically modified herpes simplex virus, IMLYGIC (talimogene laherparepvec), has also been approved for local oncolytic viral therapy of unresectable cutaneous, subcutaneous, and nodal melanoma lesions after postsurgical recurrence. There are now hundreds of gene and cell therapies in the FDA approval pipeline, on pace to reach as many as 10 to 20 related approvals per year by 2025.

Gene therapy relies on viral vectors like AAV or lentiviral vectors, which deliver the desirable genetic sequences into the cells of the target tissue. To produce enough material for clinical use, the viral vectors must be propagated in a host cell such as HEK293. Cultured cells and viral vector products destined for cell and gene therapy or other clinical cGMP applications must meet the highest standards for manufacturing quality, safety, performance, consistency, and efficiency. InVitria has carefully optimized its animal-free, serum-free, defined media formulations for clinically and industrially significant cultured cell lines. InVitria’s product line and media formulations services take the guesswork out of transitioning to regulatory-friendly, serum-reduced, or serum-free cell culture for your RUO or cGMP needs.

InVitria’s Products for Gene Therapy Include:

  • Cellastim S recombinant human albumin to replace BSA or purified human albumin in cell culture.
  • Exbumin excipient-grade recombinant human albumin for improving stability of viral vector particles in injectable therapeutics.
  • Optiferrin recombinant human transferrin for managing iron in serum-free or serum-reduced culture applications.
  • Insulin-transferrin supplements provide supplemental rh-insulin, rh-transferrin, and selenium, with or without ethanolamine and rh-albumin for serum-free or serum-reduced culture applications.
NameFunctionRecombinantHuman sequenceAnimal FreeBlood FreeIgG FreeAvailable grades
Individual Cell Culture Components
Cellastim SAnimal-free, serum-free recombinant human albumin to replace BSA and FBS in cell culture✅✅✅✅✅cGMP
ExbuminExcipient-grade, animal-free, serum-free recombinant human albumin to improve viral stability in gene therapies and vaccines. Exbumin is approved for use as an excipient in injectable therapeutics.✅✅✅✅✅cGMP
OptiferrinAnimal-free, recombinant transferrin designed to enhance cell growth and transfection efficiency in gene therapy applications.✅✅✅✅✅cGMP
ITS, ITSE, ITSE+A Insulin-Transferrin SupplementsProvides supplemental rh-insulin rh-transferrin, and selenium, with or without ethanolamine and rh-albumin for serum-free or serum-reduced culture applications.✅✅✅✅✅cGMP

Related Products

  • Cellastim® S – Recombinant human albumin
  • Exbumin® – Recombinant human albumin excipient
  • Optiferrin® – Recombinant human transferrin
  • Optibumin ® 20 – Recombinant human albumin

Transient Transfection Enhancement – Improve Transfection Efficiency Using Recombinant Transferrin

Featured Product Image
Learn More
  • 2718 Industrial Drive • Junction City, KS 66441
  • 800-916-8311
  • © 2025 InVitria

    • Terms
    • Privacy
    • Sitemap